Storia in 4 fonti

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 mesi fa

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

originale

Timeline cronologica

venerdì 29 maggio 2026·fiercepharma.com
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw…
sabato 30 maggio 2026·fiercepharma.com
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant…

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

Confronto fonti

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

Timeline cronologica

ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype

ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery…

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…

ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain